Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
CIHHF China Merchants Bank Co Ltd
BBY Best Buy Co Inc
BDGE Bridge Bancorp Inc
FFIC Flushing Financial Corp
TSC TriState Capital Holdings Inc
CSQPF Cervus Equipment Corp
IMXI International Money Express Inc
MDCO Medicines Co
TVETF Traverse Energy Ltd
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Price
Delayed
$2.13
Day's Change
0.0499 (2.40%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.35
Day's Low
2.00
Volume
(Light)

Today's volume of 492,478 shares is on pace to be much lighter than VXRT's 10-day average volume of 3,555,464 shares.

492,478

Aurora Cannabis's stock slips as revenue growth outlook falls shy of some estimates

7:27 am ET January 8, 2019 (MarketWatch)
Print

Canada-based Aurora Cannabis Inc. said Tuesday fiscal second-quarter revenue would be about 4-to-5 times what it was a year ago. The company now expects revenue of C$50 million to C$55 million, net of excise taxes, compared with C$11.7 million a year ago, and C$29.7 million in the sequential first quarter. The U.S.-listed shares slipped 0.4% in permarket trade, as the revenue outlook was below the range of estimates of two analysts surveyed by FactSet of C$60.0 million to C$74.8 million. Aurora affirmed its expectation of achieving production capacity of "at least" 150,000 kilograms/annum within the first three months of 2019. "Going forward, we see sustained strong demand from the adult usage market, as evidenced by public statements from the Canadian provinces, as well as strong patient-driven demand for medical cannabis in Canada and abroad," said Chief Executive Terry Booth. "These factors, together with our focus on disciplined management of operating expenses, and our growing portfolio of higher margin products, put us in a position to rapidly achieve positive EBITDA within the next two quarters." The stock has tumbled 49.7% over the past three months through Monday, while the ETFMG Alternative Harvest ETF (MJ) has dropped 29.4% and the S&P 500 has declined 11.6%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 08, 2019 07:27 ET (12:27 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.